Abstract 95P
Background
The type of liver resection (anatomical resection, AR or nonanatomical resection, NAR) for colorectal liver metastases (CRLM) is subject to debate. The debate may persist because some certain prognostic implications, associated with worse biological behavior of tumors, have been overlooked. The aim of this study was to explore the characteristics of patients who would benefit more from the performance of AR.
Methods
475 patients who underwent hepatic resection of CRLM were included and stratified by KRAS/NRAS/BRAF mutational status. The Kaplan-Meier method was applied in relapse-free survival (RFS), and the Cox proportional hazards model was used to identify independent predictors of prognosis in multivariable analysis.
Results
Among all 475 patients, 154 (32.4%) underwent AR and 321 (67.6%) underwent NAR. 1-, 2-, and 3-year RFS for the entire cohort were 63.0%, 40.6%, and 31.2% respectively. In the cohort of patients with KRAS/NRAS/BRAF mutated tumors, patients who underwent AR had a markedly improved median RFS compared with patients who underwent NAR (24.1 VS. 12.9 months, P = 0.005). Upon the multivariable analyses, the performance of AR (hazard ratios=0.562; 95% CI 0.370-0.854, P = 0.007) remained prognostic independently for a superior RFS. In contrast, in the cohort of patients with KRAS/NRAS/BRAF wild-type tumors, patients who underwent AR had a comparable median RFS compared with those who underwent NAR (24.9 VS. 20.3 months, P = 0.901).
Conclusions
Patients with KRAS/NRAS/BRAF mutated tumors may benefit more from the performance of AR than from the performance of NAR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract